Cypress Capital Group decreased its holdings in Clorox Co (NYSE:CLX) by 20.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,557 shares of the company’s stock after selling 1,179 shares during the quarter. Cypress Capital Group’s holdings in Clorox were worth $601,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the business. Valley National Advisers Inc. increased its position in shares of Clorox by 0.6% in the second quarter. Valley National Advisers Inc. now owns 865 shares of the company’s stock valued at $115,000 after buying an additional 5 shares in the last quarter. Blue Chip Partners Inc. increased its position in shares of Clorox by 3.9% in the second quarter. Blue Chip Partners Inc. now owns 941 shares of the company’s stock valued at $125,000 after buying an additional 35 shares in the last quarter. Sun Life Financial INC increased its position in shares of Clorox by 10,344.4% in the second quarter. Sun Life Financial INC now owns 940 shares of the company’s stock valued at $125,000 after buying an additional 931 shares in the last quarter. Acrospire Investment Management LLC purchased a new position in shares of Clorox in the second quarter valued at $133,000. Finally, Welch Group LLC increased its position in shares of Clorox by 16.2% in the second quarter. Welch Group LLC now owns 1,228 shares of the company’s stock valued at $164,000 after buying an additional 171 shares in the last quarter. Hedge funds and other institutional investors own 73.42% of the company’s stock.

CLX has been the subject of a number of research analyst reports. Zacks Investment Research cut Clorox from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Jefferies Group restated a “hold” rating and issued a $132.00 price target (down previously from $137.00) on shares of Clorox in a research report on Friday, October 6th. Morgan Stanley dropped their price target on Clorox from $138.00 to $128.00 and set an “equal weight” rating for the company in a research report on Thursday, November 2nd. Consumer Edge upgraded Clorox from a “neutral” rating to an “outperform” rating in a research report on Friday, November 10th. Finally, BMO Capital Markets restated a “buy” rating and issued a $150.00 price target on shares of Clorox in a research report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. Clorox has an average rating of “Hold” and an average price target of $128.72.

In related news, SVP Michael R. Costello sold 10,574 shares of Clorox stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the completion of the sale, the senior vice president now owns 34,867 shares in the company, valued at approximately $4,742,260.67. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Matthew T. Laszlo sold 20,051 shares of Clorox stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total value of $2,615,853.46. Following the sale, the senior vice president now owns 10,896 shares of the company’s stock, valued at approximately $1,421,492.16. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

Shares of Clorox Co (NYSE:CLX) opened at $145.15 on Wednesday. The company has a market capitalization of $18,702.54, a PE ratio of 26.14, a P/E/G ratio of 3.95 and a beta of 0.43. Clorox Co has a 52-week low of $115.00 and a 52-week high of $145.69. The company has a debt-to-equity ratio of 3.02, a quick ratio of 0.77 and a current ratio of 1.10.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.48 billion. Clorox had a return on equity of 161.59% and a net margin of 11.84%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.36 EPS. analysts expect that Clorox Co will post 5.6 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Wednesday, January 24th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. The ex-dividend date of this dividend is Tuesday, January 23rd. Clorox’s dividend payout ratio is presently 61.88%.

ILLEGAL ACTIVITY WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/clorox-co-clx-shares-sold-by-cypress-capital-group/1761072.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with Analyst Ratings Network's FREE daily email newsletter.